Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF Oct. 21, 2016 | Archived Issues

Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - October 2016 (PDF)  


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue.

Submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Figlin to Lead Initiative to Integrate Cancer Care

Robert A. Figlin, MD

Robert A. Figlin, MD

In an effort to standardize cancer care and ensure optimal treatment of patients, Cedars-Sinai has appointed Robert A. Figlin, MD, to integrate research and clinical strategies across the organization.

Figlin will serve as deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute. Previously, he was director of the Hematology Oncology Division at the institute. He will remain in this position until a successor can be found.

In his new role, Figlin will work with clinicians and investigators to unify the health system’s approach to treating cancer. The integration of cancer care means that patients will get the same level of quality services whether they’re treated at Cedars-Sinai’s main campus or at one of its highly regarded affiliates, including Tower Hematology Oncology and The Angeles Clinic.

"Dr. Figlin was tailor-made to do this," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and professor of Medicine at Cedars-Sinai. "He’s an experienced leader who knows cancer care in the Cedars-Sinai system, throughout Los Angeles and beyond."

A kidney cancer specialist, Figlin will continue working to develop clinical trials, translate research findings from the laboratory to the clinical setting and lead initiatives such as Cedars-Sinai’s effort to contain the high cost of cancer drugs.

Figlin, who joined Cedars-Sinai six years ago, is the Steven Spielberg Family Chair in Hematology Oncology. Since his arrival, he has established the Experimental Therapeutics Program and successfully recruited clinical and research faculty in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship and cancer biology, among many other achievements.

His new position, he says, will provide additional opportunities to enhance the lives of cancer patients, while advancing significant research goals.

"This position presents an opportunity to improve cancer care for our patients at Cedars-Sinai," Figlin said. "Contributing to cancer science allows me to wake up each day and feel as though I’m making an important difference."